FebriDx® Method Comparison Study Protocol
NCT06746259
Recruiting
The goal of this observational study is to learn about the performance and ease of use of FebriDx when operated by persons without laboratory experience or training in patients with acute respiratory symptoms. The main question it aims to answer is: • Is FebriDx accurate at differentiating bacterial from non-bacterial respiratory infections when used by untrained operators? Trained and untrained participants will run the FebriDx test on patients with respiratory symptoms to evaluate comparabili... Read More
Gender:
ALL
Ages:
Between 12 years and 64 years
Trial Updated:
03/03/2025
Locations: Ascada Health, Fullerton, California +7 locations
Conditions: Acute Respiratory Infections (ARIs)
Register for Updates
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
NCT04022616
Recruiting
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Breast Cancer
Register for Updates
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
NCT04704271
Recruiting
The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/03/2025
Locations: Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, West Haven, Connecticut
Conditions: Cannabis
Register for Updates
Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
NCT05120284
Recruiting
Conduct a multicenter, open label Phase IIA trial of oral DCA in 40 surgical patients with recurrent GBM who have clinically indicated debulking surgery planned. No patients will be recruited at UF. Patients will be genotyped to establish safe dosing regimens and will be randomized to receive DCA (N=20) or no DCA (N=20) for one week prior to surgery. Deidentified blood and tumor tissue obtained at surgery will be assessed at UF for biochemical markers of DCA dynamics.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/03/2025
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland +1 locations
Conditions: Glioblastoma Multiforme
Register for Updates
The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
NCT05692596
Recruiting
The long-term goal of our PIC is to develop effective strategies that can be applied clinically at the point-of-care to prevent, intercept, or detect PDAC at an early stage, thereby reducing PDAC burden and saving lives.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas, Genetic Pancreatic Cancer, Genetic Pancreatitis, BRCA Mutation, Lynch Syndrome, FAP, Familial Atypical Multiple Mole-Melanoma, PALB2 Gene Mutation, Peutz-Jeghers Syndrome, Ataxia Telangiectasia
Register for Updates
A Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
NCT05929235
Recruiting
The goal of this clinical trial is to study the safety and tolerability in all advanced solid tumors, including advanced urothelial carcinoma. The main question\[s\] it aims to answer are: * Is FX-909 safe and tolerable * What is the right dose level for patients Participants will be asked to take FX-909 daily , in tablet form and record any outcomes from taking the drug. Participants will also be asked to return for multiple site visits for various blood tests and to collect blood and tumor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: HonorHealth, Scottsdale, Arizona +11 locations
Conditions: Advanced Solid Tumors Cancer, Advanced Urothelial Carcinoma, Oral Drug Administration, Open Label
Register for Updates
Cognitive Rehabilitation in Post-COVID-19 Syndrome
NCT06136871
Recruiting
The first aim of this study is to determine the feasibility of delivering CO-OP remotely to individuals experiencing cognitive impairments that limit everyday activities in post-COVID-19 syndrome (PCS). The second aim of this study is to assess the effect of CO-OP on activity performance, subjective and objective cognition, and quality of life in a sample of individuals with PCS. The research team hypothesizes that effect size estimations will indicate that CO-OP will have a greater positive eff... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/03/2025
Locations: University of Missouri Department of Occupational Therapy, Columbia, Missouri
Conditions: Post-COVID-19 Syndrome
Register for Updates
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392
Recruiting
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
03/03/2025
Locations: Research Site, Birmingham, Alabama +179 locations
Conditions: Gastric Cancer, Gastroesophageal Junction Cancer
Register for Updates
Babies' Brain Responses to Strangers
NCT06550245
Recruiting
Researchers at the Diversity in Development Lab at UC Santa Cruz are investigating how babies' brain activities respond to people from familiar and unfamiliar racial backgrounds.
Gender:
ALL
Ages:
Between 7 months and 12 months
Trial Updated:
03/03/2025
Locations: Social Science 2 Building, Santa Cruz, California
Conditions: Infant Development
Register for Updates
A Study of SER-155 to Treat Diarrhea in People on Immunotherapy
NCT06801067
Recruiting
The purpose of this study is to find out whether SER-155 may be a safe first treatment that causes few or mild side effects for people due to irEC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Diarrhea, Enterocolitis
Register for Updates
Polycystic Kidney Disease Data Repository
NCT00792155
Recruiting
Autosomal dominant polycystic kidney disease (PKD) is the most common inherited kidney disease, affecting more than 400,000 people in the U.S. and 5 million people worldwide. PKD is the 4th most common cause of kidney failure requiring dialysis and/or transplantation. Over half of all PKD patients develop kidney failure by age 60 years, although age of onset of kidney disease varies widely, even among members of the same family. Despite the fact this is a relatively common problem, relatively f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: The Rogosin Institute, New York, New York
Conditions: Polycystic Kidney Disease
Register for Updates
Mindfulness in Chronic Kidney Disease
NCT04099992
Recruiting
This study will test whether mindfulness meditation (MM) improves sympathetic function in chronic kidney disease (CKD) and whether transcutaneous vagus nerve stimulation (tVNS) optimizes the sympatho-inhibitory effects of mindfulness meditation (MM) and restores autonomic balance in CKD patients.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
03/03/2025
Locations: Atlanta VA Medical Center, Atlanta, Georgia
Conditions: Chronic Kidney Diseases
Register for Updates